1. Introduction {#sec1-molecules-23-03012}
===============

The main route of tryptophan (TRP) degradation is through kynurenine pathway (KP) accounting for \~95% of its overall degradation. The KP leads to production of metabolites, such as kynurenic acid (KYNA), kynurenine (KYN), anthranilic acid (AA), 3-OH kynurenine (3-OH KYN), xanthurenic acid (XA), 3-hydroxybutyrate anthranilic acid (3-HAA), quinolinic acid (QA) subsequently denoted as kynurenines and, finally, to biosynthesis of a crucial cofactor, namely, nicotinamide adenine dinucleotide (NAD+) \[[@B1-molecules-23-03012]\]. The process of metabolizing TRP into KYN takes place in different locations mostly in the liver, kidneys and the brain with the help of three enzymes: TRP-2,3-dioxygenase, indoleamine-2,3-dioxygenase-1 and indoleamine dioxygenase---2 \[[@B1-molecules-23-03012],[@B2-molecules-23-03012]\]. It should be emphasized that humans are not able to synthesize TRP by themselves, therefore, it comes only from the diet. In recent years, many researches have proven a significant role of the KP in the pathogenesis of several serious disorders, such as cancer, psychiatric, neurodegenerative and autoimmune system dysfunctions \[[@B3-molecules-23-03012]\]. The examination of TRP metabolites levels has been studied in brain tissue and amniotic fluid \[[@B4-molecules-23-03012]\], serum \[[@B5-molecules-23-03012],[@B6-molecules-23-03012]\] cerebrospinal fluid \[[@B7-molecules-23-03012]\], human cataracts' lenses \[[@B8-molecules-23-03012]\] and saliva of a diabetic patient \[[@B9-molecules-23-03012]\]. There is also evidence that the KP pathway is connected with visual function as KYN and 3-OH-KYN glycoside derivatives act as UV filters and protect the retina and the lens by absorbing the UV radiation \[[@B8-molecules-23-03012],[@B10-molecules-23-03012],[@B11-molecules-23-03012],[@B12-molecules-23-03012],[@B13-molecules-23-03012],[@B14-molecules-23-03012]\]. On the other hand, the kynurenine pathway-derivatives were identified as compounds inducing that is, cataract formation \[[@B8-molecules-23-03012],[@B10-molecules-23-03012],[@B14-molecules-23-03012]\]. Till now determination of TRP catabolites has been developed by a sensitive, rapid and specific high-performance liquid chromatography coupled to tandem mass spectrometry, however, ultra-violet or fluorescent absorbance and electrochemical detectors can be also applied for this purpose \[[@B15-molecules-23-03012],[@B16-molecules-23-03012],[@B17-molecules-23-03012],[@B18-molecules-23-03012],[@B19-molecules-23-03012],[@B20-molecules-23-03012],[@B21-molecules-23-03012],[@B22-molecules-23-03012],[@B23-molecules-23-03012],[@B24-molecules-23-03012],[@B25-molecules-23-03012]\].

The goal of this study was to quantify of tryptophan and its major metabolites, kynurenine and kynurenic acid by LC-MS/MS using [l]{.smallcaps}-tryptophan-amino-15N, 99 ATOM % 15N as an internal standard. The elaborated method was assessed for validation parameters. Feasibility of the method was demonstrated in fluid from the anterior chamber of the eye in patients. Patients were divided into those with cataracts and compared to patients with coexisting diabetes. To test differences between the groups, the experimental results have been analysed by a statistical method. The levels of TRP, KYN, KYNA, the ratios of catabolites to each other were considered as the factors. Additionally, the age of patients was considered as an independent variable.

2. Results and Discussion {#sec2-molecules-23-03012}
=========================

LC/MS/MS as an essential method to identify and quantify TRP and its kynurenine metabolites was applied to the present study. Our procedure was based on a simple "dilute-and-shoot" liquid chromatography-tandem mass spectrometry (LC-MS/MS) method which was previously used for the simultaneous quantitation of drugs of abuse, in biological samples for forensic toxicology purposes \[[@B26-molecules-23-03012],[@B27-molecules-23-03012]\]. UHPLC ensured and improved either throughput and sensitivity of the method.

The elaborated conditions ensured successful separation of examined analytes within 2 min ([Figure 1](#molecules-23-03012-f001){ref-type="fig"}).

Proposed procedure was subjected to a number of validation criteria as, so far, there is no studies describing analysis of TRP metabolites in the fluid from the anterior chamber of the eye. A linear response of the peak area was observed over a concentration range of 4--2000 ng mL^−1^. It should be emphasized that such a wide range of the calibration curve from 4--2000 is acceptable for API instrument \[[@B28-molecules-23-03012],[@B29-molecules-23-03012]\]. The correlation coefficient values obtained from plotting the peak area against the nominal concentration were higher than 0.99 at each case. Linearity was observed for each concentration range between this at the LOD and the highest concentrations tested. The parameters of the linear regression function are collected in [Table 1](#molecules-23-03012-t001){ref-type="table"}.

LOD and LOQ were calculated as the analyte concentrations which give rise to peaks 3 and 10 times higher than the baseline noise, respectively, varied between 0.2 and 1.20 ng/mL for LOD and 0.66 and 3.9 ng/mL for LOQ ([Table 2](#molecules-23-03012-t002){ref-type="table"}).

The relative recoveries were estimated by measuring spiked samples of TRP, KYN, KYNA at four concentrations with 3 replicates of each. No statistically significant differences were noticed for the lower and higher concentrations as shown in [Table 3](#molecules-23-03012-t003){ref-type="table"}. Because the fluid from the anterior chamber of the eye without tryptophan and its metabolites does not exist, purified water was used as a matrix. As shown, recoveries of TRP, KYN and KYNA varied between 94.3--96.1%, 91--95% and 96--97.6% respectively.

The method provided satisfactory precision expressed by relative standard deviation values. Precision values expressed as RSD% values were lower than 5% for repeatability (intra-day precision) and lower than 7% for intermediate precision (reproducibility, inter-day precision).

The results in [Table 4](#molecules-23-03012-t004){ref-type="table"} show content of the kynurenine metabolites determined in aqueous humour of 28 subjects who underwent cataract extraction surgery. All clinical samples have been divided into two groups: the first group including patients with cataract and the second one with cataract with coexisting diabetes.

The concentrations of KYN and KYNA were significantly higher in patients with diabetes in comparison to cataracts alone. There were no differences in concentration of TRP and other metabolites ratios between the studied groups. The increased concentrations of KYN and KYNA in patients with diabetes suggest an altered metabolism of TRP.

3. Materials and Methods {#sec3-molecules-23-03012}
========================

3.1. Sample Collection {#sec3dot1-molecules-23-03012}
----------------------

Performed experiments were done in agreement obtained by the Bioethics Commission of the Medical University of Lublin. Twenty-eight samples of fluid from the anterior chamber of the eye were collected at the beginning of cataract extraction surgery. The samples were stored in 1.5 mL polypropylene tubes at −80 °C until analysis.

3.2. Sample Preparation {#sec3dot2-molecules-23-03012}
-----------------------

The purification was based on Dilute and Shoot (D&S) method. Briefly, 15 μL of the fluid from the anterior chamber of the eye was diluted by 15 μL of internal standards ([l]{.smallcaps}-tryptophan-amino-15N) and 30 μL of 0.1% formic acid in water. Then, 10 μL was injected into LC-MS/MS.

3.3. LC-MS/MS {#sec3dot3-molecules-23-03012}
-------------

The UHPLC-MS/MS system consisting of an AB Sciex ExionLC UHPLC system connected to an AB Sciex API 5500 Qtrap mass spectrometer (AB Sciex, Concord, ON, Canada). Analyst 1.6.3 software (AB Sciex) controlled the UHPLC-MS/MS system and Multiquant 3.2 (AB Sciex) was used to process the data. The mass spectrometer was operated in the positive ESI mode with a capillary voltage of 4.5 kV. The temperature of desolvation was set at 600 °C, nebuliser gas (N~2~)--40; curtain gas (N~2~)--40; collision gas (N~2~)--medium; gas 1 (air)--35; gas 2 (air)--35. The multiplier was set at 2300 V. The flow rate of mobile phase was 600 μL min^−1^, the injection volume--10 μL. The chromatography was performed on a Synergi 4 μ Fusion-RP column (50 mm × 2 mm × 4 μm), connected to a C18 precolumn (4 mm × 2 mm × 4 μm). The mobile phase for LC analysis consisted of two solutions: A (0.1% formic acid in water) and B (acetonitrile). The mobile phase gradient program started at 1% of B, 98% B at 0.55 min to 1 min, then 1% of B at 1.1 min and held for 1.9 min. The column was equilibrated for 2 min. The column operated at 40 °C and the ions were monitored in Multiple Reaction Monitoring (MRM) mode ([Table 6](#molecules-23-03012-t006){ref-type="table"}).

3.4. Validation {#sec3dot4-molecules-23-03012}
---------------

The analytical-method validation was carried out according to the ICH Q2 (R1) method-validation guidelines \[[@B30-molecules-23-03012]\] and others \[[@B31-molecules-23-03012],[@B32-molecules-23-03012],[@B33-molecules-23-03012]\]. The following validation parameters were established: selectivity, linearity, precision, LOD and LOQ. The method validation was also based on other literature data, describing an analysis of endogenous compounds in a biological matrix \[[@B34-molecules-23-03012],[@B35-molecules-23-03012]\].

### 3.4.1. Calibration Solutions and Standards {#sec3dot4dot1-molecules-23-03012}

Analyte standard solutions at different concentrations: 4, 10, 50, 150, 400, 2000 ng/mL were added to the blank sample, subjected to the D&S and HPLC procedure. The analyte peak area was plotted against the corresponding concentrations and the calibration curves were set up by means of the least-squares method.

### 3.4.2. LOD and LOQ {#sec3dot4dot2-molecules-23-03012}

LOD and LOQ were estimated by calculations based on Signal-to-Noise ratio. Determination of the signal-to-noise ratio is performed by comparing measured signals from samples with known low concentrations of analyte with those of blank samples and establishing the minimum concentration at which the analyte can be reliably detected or quantified concentration at which the analyte can be reliably quantified. A typical signal-to-noise ratio is 3:1 for LOD and 10:1 LOQ.

### 3.4.3. Precision {#sec3dot4dot3-molecules-23-03012}

Spiked blank samples were prepared as follows: 15 μL of standard solution of different concentration were added to 15 μL of the water and was diluted by 15 μL of internal standards ([l]{.smallcaps}-tryptophan-amino-15N) and 15 μL of 0.1% formic acid in water. At least four concentrations were prepared and analysed for each compound, corresponding to the lower, two middle and upper limit of the respective linearity curve. Spiked blank samples were prepared and analysed according to the described procedure. The analysis was repeated twelve times giving intraday precision values and twelve times in another day giving intermediate precision values, both expressed as RSD%.

3.5. Statistical Analysis {#sec3dot5-molecules-23-03012}
-------------------------

The statistical analysis was carried out in the STATISTICA versus 12 program using the Mann-Whitney U-test. The statistical significance level was assumed for *p* values \<0.05.

4. Conclusions {#sec4-molecules-23-03012}
==============

Examination of tryptophan metabolism can help to understand an aetiology as well as consequences of many diseases. Experiments on the fluid from the anterior chamber of the eye suggest that neuroactive metabolites of the tryptophan (TRP) in the kynurenine pathway (KP) may play a significant role in cataract formation in patients suffering from diabetes. The elevation of KYNA levels has been previously observed in cataractous lenses \[[@B8-molecules-23-03012]\]. Our study has proven the increased content of KYN and KYNA and the ratio of TRP/KYN in the eye fluid of cataract patients suffering from diabetes. Obtained results, similarly to literature data, confirm that tryptophan metabolism is not only dysregulated during diabetes but also affects ophthalmological complications.

However, there is a need for further experiments in the aim to support the obtained results and fully explain the role of tryptophan metabolism in the pathogenesis of cataracts in diabetic patients.

**Sample Availability:** Samples of L-tryptophan-amino-15N, L-tryptophan, L-kynurenine and L-kynurenic acid are not available from the authors but it can be purchased from the manufacturer: Sigma-Aldrich (St. Louis, MO, USA).
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###### 

Chromatograms obtained from analysis of standards of IS (**A**), tryptophan (**B**), kynurenine (**C**), kynurenic acid (**D**) by LC-MS/MS.
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![The box-plots representing statistically significant differences between the levels of KYNA (**A**), KYN (**B**) and ratio TRP/KYN (**C**) in patients with both studied groups.](molecules-23-03012-g002){#molecules-23-03012-f002}
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###### 

Parameters obtained for the calibration curve.

  Analyte          Concentration Range (ng/mL)   Determination Coefficient   Calibration Curve
  ---------------- ----------------------------- --------------------------- ------------------------------------------
  Tryptophan       4--2000                       0.9973                      y = 0.0213 (±0.0015)x − 0.0330 (±0.0023)
  Kynurenine       4--2000                       0.9972                      y = 0.0325 (±0.0030)x − 0.0325 (±0.0030)
  Kynurenic acid   4--2000                       0.9982                      y = 0.0088 (±0.0010)x − 0.1097 (±0.0121)

molecules-23-03012-t002_Table 2

###### 

LOQ and LOD values.

  Analyte       Tryptophan   Kynurenine   Kynurenic Acid
  ------------- ------------ ------------ ----------------
  LOD (ng/mL)   0.20         1.20         0.40
  LOQ (ng/mL)   0.66         3.9          1.32
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###### 

Validation parameters.

  ------------------------------------------------ ---------------- ------------ ------------ ------------
  **Parameters**                                   Tryptophan                                 
  Fortification level (ng/mL)                      50               150          400          2000
  Average recovery (*n* = 18) (%)                  95.0 ± 3.2       96.1 ± 3.4   98.0 ± 4.0   94.3 ± 2.2
  Average repeatability, (RSDr, %)                 4.4 ± 3.4        3.4 ± 2.2    3.6 ± 3.9    4.1 ± 4.1
  Average within-lab reproducibility, (RSDwR, %)   5.7 ± 3.2        5.0 ± 3.0    5.2 ± 2.0    5.4 ± 3.8
                                                   Kynurenine                                 
  Fortification level (ng/mL)                      10               50           150          400
  Average recovery (*n* = 18) (%)                  91.0 ± 4.6       92.2 ± 4.2   94.6 ± 3.0   95.0 ± 4.3
  Average repeatability, (RSDr, %)                 5.5 ± 3.9        4.9 ± 4.4    5.1 ± 4.3    6.4 ± 4.1
  Average within-lab reproducibility, (RSDwR, %)   6.9 ± 5.3        5.1 ± 4.3    4.8 ± 4.5    5.8 ± 5.2
                                                   Kynurenic acid                             
  Fortification level (ng/mL)                      4                10           50           150
  Average recovery (*n* = 18) (%)                  96.0 ± 3.7       96.3 ± 3.5   97.2 ± 3.8   97.6 ± 2.6
  Average repeatability, (RSDr, %)                 5.0 ± 3.6        3.6 ± 2.9    3.2 ± 3.4    4.0 ± 3.7
  Average within-lab reproducibility, (RSDwR, %)   5.3 ± 3.9        4.2 ± 3.3    4.4 ± 2.9    4.6 ± 3.2
  ------------------------------------------------ ---------------- ------------ ------------ ------------
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###### 

The level of TRP, KYNA and KYN \[ng/mL\] and metabolites ratios determined in eye fluid for the retrospective case series of 28 patients suffered from cataracts including 8 patients with coexisting diabetes.

  -------------- ------------------------------------- ------------------ -------- -------
                 **Diabetes and Cataract (*n* = 8)**                               
  **Range**      **Mean ± Standard Deviation**         **Median**         **CV**   
  KYN (ng/mL)    21.85--191.84                         64.06 ± 56.17      41.93    0.876
  KYNA (ng/mL)   6.22--8.51                            6.94 ± 0.72        6.78     0.104
  TRP (ng/mL)    694.86--1784.12                       1010.69 ± 387.45   817.76   0.383
  TRP/KYNA       101.57--256.80                        145.53 ± 53.36     125.81   0.367
  TRP/KYN        9.33--33.46                           20.59 ± 8.72       19.23    0.423
  KYN/KYNA       3.40--27.54                           9.29 ± 8.12        6.51     0.874
                 **Cataract (n = 20)**                                             
  **Range**      **Mean ± Standard Deviation**         **Median**         **CV**   
  KYN (ng/mL)    16.61--67.84                          31.11 ± 14.59      27.37    0.469
  KYNA (ng/mL)   5.83--6.76                            6.19 ± 0.23        6.17     0.038
  TRP (ng/mL)    465.36--1356.26                       855.57 ± 203.13    835.02   0.237
  TRP/KYNA       75.72--219.30                         138.03 ± 31.00     132.25   0.225
  TRP/KYN        6.86--53.91                           32.12 ± 11.72      32.36    0.365
  KYN/KYNA       2.71--11.03                           5.01 ± 2.29        4.42     0.457
  -------------- ------------------------------------- ------------------ -------- -------

Data was presented as mean ± standard deviation and was all tested for homogeneity of variance by the Bartlett test at first. It appeared that obtained data did not follow the normal distribution. To compare two independent data coming from distinct populations, which can not affect each other, namely, "cataract group" and "diabetes group", the Manna--Whitney-U test corrected for ties has been applied ([Table 5](#molecules-23-03012-t005){ref-type="table"}). Besides the content of metabolites, data expressing the following ratios TRP/KYNA, TRP/KYN, KYN/KYNA, has been added as an additional variable. Obtained values of *p* indicate existence of the significant differences between "cataract group" and "diabetes group" regarding the level of KYN, KYNA and the ratio of TRP/KYN ([Table 5](#molecules-23-03012-t005){ref-type="table"}, [Figure 2](#molecules-23-03012-f002){ref-type="fig"}). We did not find any correlations between remaining estimated parameters.
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###### 

The Manna--Whitney-U test corrected for ties. Marked tests are significant at *p* \< 0.05000.

  Variables        The Sum of a Rank for Diabetics Group   The Sum of a Rank for Cataract Group   U        Z         *p*      Z (Corrected for Ties)   P        2\*1 P
  ---------------- --------------------------------------- -------------------------------------- -------- --------- -------- ------------------------ -------- --------
  KYNA             185.00                                  221.00                                 11.00    3.4836    0.0005   3.4836                   0.0005   0.0001
  KYN              161.00                                  245.00                                 35.00    2.2630    0.0236   2.2630                   0.0236   0.0213
  TRP              120.00                                  286.00                                 76.00    0.1780    0.8587   0.1780                   0.8587   0.8617
  TRP/KYNA         108.00                                  298.00                                 72.00    −0.3814   0.7029   −0.3814                  0.7029   0.7086
  TRP/KYN          71.00                                   335.00                                 35.00    −2.2630   0.0236   −2.2630                  0.0236   0.0213
  KYN/KYNA         150.00                                  256.00                                 46.00    1.7036    0.0885   1.7036                   0.0885   0.0887
  Age of patient   83.00                                   323.00                                 47.000   −1.6528   0.0984   −1.6562                  0.0977   0.0991

U---the values of the Mann-Whitney test when the group size is less than 20, Z---Mann Whitney test value when the group size is greater than 20, *p*---probability value for the test for value of the test statistics Z, Z---test statistic Z (corrected for ties), P---probability value for test statistic Z (corrected for ties), 2\*1 P---probability value when the group size is less than 20.
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###### 

Precursor ions and fragment ions of tryptophan, kynurenine, kynurenic acid and internal standards---mass spectrometry parameters.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analyte          Precursor Ion (m/z)   Ion Transition   Declustering Potential   Collision Energy (eV)   Collision Cell Exit Potential   Entrance Potential
  ---------------- --------------------- ---------------- ------------------------ ----------------------- ------------------------------- --------------------
  Tryptophan       205.0                 188.0\           50                       16\                     16\                             10\
                                         146.0                                     23                      10                              10

  Kynurenine       209.1                 191.9\           66                       11\                     14\                             10\
                                         146.0                                     25                      10                              10

  Kynurenic acid   190.0                 172.0\           81                       17\                     12\                             10\
                                         144.0                                     25                      14                              10

  (IS)             206.0                 188.0            50                       16                      16                              10
  -------------------------------------------------------------------------------------------------------------------------------------------------------------
